Why this analyst says selloff in this stock "is a misunderstanding"

October 5, 2026 8:00 PM

Oppenheimer reiterated an Outperform rating on a clinical-stage biotech after its shares fell sharply last week following a detailed data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found